Drug Pricing & Part D
Expert articles and analysis related to drug pricing & part d.
AI Summary — Last 24 Hours
CMS extended the application deadline for drug manufacturers in the Medicaid-focused GENEROUS Model, signaling strong pharma interest in a Trump administration test of outcomes- and affordability-oriented drug pricing tools that could affect state Medicaid purchasing strategy and supplemental rebate dynamics. At the same time, CMS’s proposed drug interoperability and prior authorization rule would push payers and providers toward more standardized electronic exchange for pharmacy benefit decisions, with near-term implications for MA, Medicaid managed care, ACO care teams, and specialty pharmacy workflows managing high-cost drugs and oncology access barriers. See: GENEROUS Model deadline extension and drug interoperability/prior authorization proposed rule summary.
Related Articles
CMS extends GENEROUS model deadline for pharma and states
The Centers for Medicare and Medicaid Services is extending the application deadline for drug manufacturers to apply to the GENErating cost Reductions fOr U.S. Medicaid Model. CMS said it made the dec...
Will Tennessee’s PBM Bill Face the Same Fate as Arkansas’ Law?
Will Tennessee’s PBM Bill Face the Same Fate as Arkansas’ Law?  MedCity News
Federal judge permanently blocks North Dakota 340B drug law
Federal judge permanently blocks North Dakota 340B drug law  Becker's Hospital Review
STAT+: FDA wants to exclude weight loss drugs from a compounding list
FDA moves to remove semaglutide, tirzepatide, and liraglutide from its 503B compounding list, saying there's no shortage of GLP-1 drugs from Novo Nordisk and Eli Lilly.
Expanding specialty pharmacy services could help health systems improve outcomes and manage chronic disease costs | Asembia AXS26 Summit
Expanding specialty pharmacy services could help health systems improve outcomes and manage chronic disease costs | Asembia AXS26 Summit  Managed Healthcare Executive
FDA seeks to restrict compounding of key GLP-1s
FDA seeks to restrict compounding of key GLP-1s  Becker's Hospital Review
Partnerships Power Access to Advanced Oncology Therapies
Partnerships Power Access to Advanced Oncology Therapies  The American Journal of Managed Care
Physician Payment Changes and MFP May Strain Independent Physicians
Ascendiun CEO: Hearings highlight need for 'systemic' change
From newsletter: The LI Daily: On Capitol Hill, health system CEOs agree to 'rational reworking' of site-neutral payments On Capitol Hill, health system CEOs agree to 'rational reworking' of site-ne...
STAT+: Her daughter Mila got a bespoke medicine. Now she’s starting a new biotech to make more
Efforts to make customized medicines at scale have hit commercial and regulatory roadblocks. Julia Vintarello is trying again.